A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7046-7053

  Khan, Khuda D ^a   Emmanouilides, Christos ^b   Benson Jr , Don M ^c   Hurst, Deborah ^e   Garcia, Pablo ^e   Michelson, Glenn ^e   Milan, Sandra ^e   Ferketich, Amy K ^c   Piro, Lawrence ^f   Leonard, John P ^g   Porcu, Pierluigi ^c,d   Eisenbeis, Charles F ^c,d   Banks, Amy L ^c   Chen, Lei ^c   Byrd, John C ^c,d   Caligiuri, Michael A ^c,d  

^a American Health Network   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Cancer Institute Medical Group   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2; RITUXIMAB;

ADULT; AGED; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GENETIC POLYMORPHISM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; RECEPTORS, IGG; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33845795327     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1571     Document Type: Article

References (33)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemia and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
4. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as a single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6.
5. Davis TA, Grillo-Lopes AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:135-43.
6. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23.
7. Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlates with clinical response. Clin Cancer Res 2004;10:2553-64.
8. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin-2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Bit J Haematol 2002;117:828-34.
9. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith K, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171: 1509-26.
10. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993;91:123-32.
11. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998;46: 318-26.
12. Eisenbeis CF, Grainger A, Fisher B, et al. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004;10:6101-10.
13. bright subset. Blood 2001;97:146-51.
14. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
15. Cohen-Solal JFG, Cassard L, Fridman WH, Sautes-Fridman C. Fc γ receptors. Immunol Lett 2004;92: 199-205.
16. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in the IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-8.
17. Goley J, Manganini M, Facchinetti V, et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003;88:1002-12.
18. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95: 3900-8.
19. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-43.
20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244-53.
21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo activity cytotoxicity against tumor cells. Nat Med 2000;6:443-6.
22. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
24. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
25. Shah M, Freud AG, Benson DM, et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993-6.
26. + regulatory T cells in cancer patients. Blood 2006;107:2409-14.
27. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
28. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Ex Med 2005;202:1075-85.
29. + regulatory T cells. Proc Natl Acad Sci 2006;103:5460-5.
30. Binstandt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol 2003;111:697-703.
31. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
32. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-69.
33. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells byTHP-1 monocytes. J Immunol 2006;176:2600-9.